Apogee's $350M of­fer­ing; Bio­mX merges with Adap­tive Phage

Plus, news about Telios Phar­ma and Celldex Ther­a­peu­tics:

An­oth­er day, an­oth­er pub­lic of­fer­ing: Apogee Ther­a­peu­tics is aim­ing to raise $350 mil­lion in a stock sale an­nounced the same day that it shared Phase I da­ta for its atopic der­mati­tis treat­ment in healthy vol­un­teers that hints at po­ten­tial­ly longer dos­ing in­ter­vals. — Jaimy Lee

Bio­mX merges with Adap­tive Phage Ther­a­peu­tics: The com­bined phage ther­a­py biotech will have two Phase II as­sets: BX004 for chron­ic pul­monary in­fec­tions in cys­tic fi­bro­sis, and BX211 for di­a­bet­ic foot os­teomyelitis. Bio­mX al­so se­cured a $50 mil­lion pri­vate place­ment to ad­vance the pro­grams through clin­i­cal read­outs in 2025. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER